Device Trial Radar · NCT01701284
Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 2012
Primary completion
May 2023
Study completion May 2023
Sponsor
- Lead sponsor
- Northwestern UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Neuronetics
- First posted
- Oct 5, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a leading cause of mortality and morbidity worldwide. In addition, cancer is associated with high rates of depression and anxiety among its sufferers, and cancer patients with depression usually have worse treatment outcomes and long-term survival. Surprisingly, many cancer patients with depression do not receive treatment for their depression, perhaps because treatments for cancer-related depression are usually adapted from those used in non-cancer populations and may not be suitable for cancer patients. Moreover, cancer patients with depression are more likely to have a long latency of anti-depressant drug action, negative drug-drug interactions with cancer chemotherapies and an increased susceptibility for systemic side effects. Repetitive transcranial magnetic stimulation (rTMS) is a new treatment modality for depression that affects the brain directly with no systemic side effects and poses no potential for drug-drug interactions. rTMS therapy was recently cleared by the FDA as an antidepressant treatment for treatment-resistant Major Depressive Disorder, and now is being evaluated for a wide array of additional psychiatric indications. This randomized, open label, two-arm, pilot study will investigate the safety, tolerability, feasibility and the efficacy of two forms of rTMS (i.e., left (fast) and right (slow) sided rTMS) in cancer-related depression. The study hypotheses are that rTMS will significantly reduce symptoms of depression and that right-sided slow rTMS will be more effective than left-sided fast rTMS for the treatment of severe anxiety.
Conditions
- Cancer in Remission (Any Type or Stage)
- Depression
- Anxiety
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Change in Depression Severity (HDRS-17) at Weeks 2, 4, and 6Time frame: Baseline (Week 0), Week 2, Week 4 and Week 6.
- Relative Change in Depression Severity (HDRS-17) at Weeks 2, 4, and 6Time frame: Baseline (Week 0), Week 2, Week 4 and Week 6
- Number of Participants With Treatment-Emergent Side Effects (UKU)Time frame: Baseline (Week 0), Week 2, Week 4, and Week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northwestern University
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.